ANALYTICAL QUANTIFICATION OF BOSUTINIB IN NANOCARRIER USING UV AND HPLC: METHOD DEVELOPMENT AND VALIDATION
DOI:
https://doi.org/10.22159/ijap.2024v16i5.51394Keywords:
Bosutinib, Lipidic nanocarriers, Cancer therapy, Drug delivery, Chromatographic analysisAbstract
Objective: Bosutinib, a potent tyrosine kinase inhibitor, holds significant promise in cancer therapy, particularly in Breast Cancer treatment. This study focuses on the analytical quantification of Bosutinib in Nanocarriers (BNCs) essential for quantification in terms of targeted delivery.
Methods: A comprehensive method development and validation process was undertaken utilizing UV-visible spectroscopy and High-Performance Liquid Chromatography (HPLC). Preformulation studies confirmed the purity and physicochemical properties of bosutinib. UV-visible spectroscopy established a calibration curve for bosutinib and BNCs, with precision, accuracy, Limits of Detection (LOD), and Limits of Quantification (LOQ) determined. HPLC analysis further validated bosutinib quantification, ensuring the robustness and reliability of the analytical method.
Results: Bosutinib and BNCs were evaluated using UV-visible spectroscopy, revealing λ max at 263 nm and 277 nm, respectively, showing a strong correlation with the regression coefficient (R2) being 0.9969 and 0.9994, respectively. The precision (intra-day and inter-day) data shows strong reproducibility with a Percentage Relative Standard Deviation (%RSD) of less than 1.5%. Completely distinguished sharp peaks of bosutinib and BNCs were developed using HPLC under ambient settings; 3.974±0.006 and 3.083±0.004 was the Resolution Time (Rt) at which bosutinib and BNCs were discovered, respectively. The Theoretical Plate (TP) values of 5179±93 and 2598±85 and the Tailing Factor (TF) of1.00±0.002 and 1.10±0.004 were both within the predetermined bounds.
Conclusion: The developed UV and HPLC methods offer accurate and reliable quantification of bosutinib in a nanocarrier, essential for optimizing drug delivery strategies and therapeutic outcomes in cancer treatment. This analytical approach contributes to advancing pharmaceutical research in precision medicine and targeted drug delivery systems.
Downloads
References
Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti Passerini C, Baccarani M, Kim DW. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12;119(15):3403-12. doi: 10.1182/blood-2011-11-390120, PMID 22371878.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5 y update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044-54. doi: 10.1038/leu.2016.5, PMID 26837842.
Gambacorti Passerini C, Kantarjian HM, Kim DW, Khoury HJ, Turkina AG, Brümmendorf TH. Long-term efficacy and safety of Bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015 Sep 1;90(9):755-68. doi: 10.1002/ajh.24034, PMID 26040495.
Bhosale Rr, Janugade Bu, Chavan Dd, Thorat Vm. Current perspectives on applications of nanoparticles for cancer management. Int J Pharm Pharm Sci. 2023;15(11):1-10.
Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853, PMID 19075254.
Ahmed S, Mustaan N, Sheraz MA, Nabi SA, Ahmad I. Validation of a UV spectrometric method for the assay of tolfenamic acid in organic solvents. J Pharm (Cairo). 2015;2015:216249. doi: 10.1155/2015/216249, PMID 26783497.
Trivedi S, Belgamwar V, Wadher K, Umekar M. Development and validation of a UV spectrophotometric method for the estimation of the synthesized lentinan-congo red complex. J Appl Spectrosc. 2022 May 1;89(2):344-9. doi: 10.1007/s10812-022-01364-y.
Chaursiya AC, Dumpala L. Q2 (R1) and new ICH Q14 guidance. Glob J Pharma. R A Rev Revision ICH. 2020 Nov 15;1(6):1-6.
Trivedi S, Belgamwar V, Wadher K. Development and validation of ultra visible spectrophotometric method for the estimation of thymoquinone. AJACR. 2021;8(2):25-30. doi: 10.9734/ajacr/2021/v8i230189.
Bhoyar V, Belgamwar VS, Trivedi S. Simultaneous determination and validation of anti-tubercular drugs in simulated lungs alveolar macrophages fluid by ultraviolet-visible spectrophotometric method. J Appl Spectrosc. 2022 Nov 1;89(5):892-7. doi: 10.1007/s10812-022-01444-z.
Wadher K, Trivedi S, Rarokar N, Umekar M. Development and assessment of rutin loaded transfersomes to improve ex vivo membrane permeability and in vitro efficacy. Hybrid Adv. 2024 Apr;5:100144. doi: 10.1016/j.hybadv.2024.100144.
Elham G, Sima S, Javad S, AI. Analytical method validation and bioequivalence study of erlotinib 150 Mg tablets in Iranian healthy volunteers under fasting condition. Int J Pharm Pharm Sci. 2023;15(1):27-32. doi: 10.22159/ijpps.2023v15i1.46475.
Trivedi S, Belgamwar V, Wadher K. Analytical profiling of lentinan in hybrid nanostructures for intranasal delivery: method development and validation. Results in Chemistry. 2022;4. doi: 10.1016/j.rechem.2022.100471.
Aderibigbe BA. In situ-based gels for nose-to-brain delivery for the treatment of neurological diseases. Pharmaceutics. 2018 Jun 1;10(2). doi: 10.3390/pharmaceutics10020040, PMID 29601486.
Trivedi S, Deshpande A, Belgamwar V, Bhoyar V, Wadher K. Stability indicating HPLC method for estimation of thymoquinone in nasal simulated fluid: method development and validation. J Pharm Res Int. 2021;33(60A):233-40. doi: 10.9734/jpri/2021/v33i60A34480.
Trivedi S, Thool S, Wadher K, Bhalekar M, Bire P. Self-assembling dioscorea bulbifera loaded mixed micelles: formulation optimization, in vitro cytotoxicity and in vivo pharmacokinetics. J Drug Deliv Sci Technol. 2021 Oct 1;65:102722. doi: 10.1016/j.jddst.2021.102722.
Wadher K, Dabre S, Gaidhane A, Trivedi S, Umekar M. Evaluation of antipsoriatic activity of gel containing Pongamia pinnata extract on imiquimod-induced psoriasis. Clin Phytosci. 2021 Dec;7(1). doi: 10.1186/s40816-021-00256-6.
Trivedi S, Kause S, Belgamwar V. Intranasal delivery of poly (D-glucosamine) encrusted self-assembled lipidic nanovesicles to enhanced brain uptake of thymoquinone for management of glioblastoma multiforme. J Drug Deliv Sci Technol. 2023 Dec 1;90. doi: 10.1016/j.jddst.2023.105149.
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan Jacob SW, Ray A. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-41. doi: 10.1016/j.ccr.2005.01.007, PMID 15710326.
Trivedi S, Wadher K, Umekar M. Development of topical thymoquinone loaded polymer-lipid hybrid vesicular gel: in vitro and ex-vivo evaluation. J Liposome Res. 2022;32(3):224-36. doi: 10.1080/08982104.2021.1929311, PMID 34003069.
Belgamwar VS, Bhoyar VT, Trivedi S, Pardeshi CV. Quantitative and qualitative analysis of direct nose-to-brain drug delivery. Direct nose-to-brain drug deliv mech Technol Adv Appl Regul Updat; 2021 Jan 1. p. 459-81.
Cortes JE, Gambacorti Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018 Jan 20;36(3):231-7. doi: 10.1200/JCO.2017.74.7162, PMID 29091516.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Rishabh Agade, Ujban Hussain, Sagar Trivedi, Veena Belgamwar
This work is licensed under a Creative Commons Attribution 4.0 International License.
